Hansa Biopharma announces $70 million non-dilutive product finance transaction with NovaQuest to support continued development of the company's antibody-cleaving enzyme technology platform

MLA

“Hansa Biopharma Announces $70 Million Non-Dilutive Product Finance Transaction with NovaQuest to Support Continued Development of the Company’s Antibody-Cleaving Enzyme Technology Platform.” Obesity, Fitness & Wellness Week, Aug. 2022, p. 36. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsggo&AN=edsgcl.712102459&authtype=sso&custid=ns315887.

APA

Hansa Biopharma announces $70 million non-dilutive product finance transaction with NovaQuest to support continued development of the company’s antibody-cleaving enzyme technology platform. (2022, August 6). Obesity, Fitness & Wellness Week, 36.

Chicago

Obesity, Fitness & Wellness Week. 2022. “Hansa Biopharma Announces $70 Million Non-Dilutive Product Finance Transaction with NovaQuest to Support Continued Development of the Company’s Antibody-Cleaving Enzyme Technology Platform,” August 6. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsggo&AN=edsgcl.712102459&authtype=sso&custid=ns315887.